Home

spotřebitel obsah Uspořádat overall response rate brát léky volba Letecká pošta

Objective response rate of placebo in randomized controlled trials of anticancer medicines - eClinicalMedicine
Objective response rate of placebo in randomized controlled trials of anticancer medicines - eClinicalMedicine

COTELLIC® (cobimetinib) + ZELBORAF® (vemurafenib) Objective Response Rate
COTELLIC® (cobimetinib) + ZELBORAF® (vemurafenib) Objective Response Rate

BRAFTOVI + cetuximab | Overall Response Rate | ORR | BEACON CRC
BRAFTOVI + cetuximab | Overall Response Rate | ORR | BEACON CRC

Efficacy | BALVERSA® (erdafitinib) HCP
Efficacy | BALVERSA® (erdafitinib) HCP

Positive plasma cotinine during platinum-based chemotherapy is associated with poor response rate in advanced non-small cell lung cancer patients | PLOS ONE
Positive plasma cotinine during platinum-based chemotherapy is associated with poor response rate in advanced non-small cell lung cancer patients | PLOS ONE

Tumor Mutational Burden and Response Rate to PD-1 Inhibition | NEJM
Tumor Mutational Burden and Response Rate to PD-1 Inhibition | NEJM

PDF] Objective response rate assessment in oncology: Current situation and future expectations | Semantic Scholar
PDF] Objective response rate assessment in oncology: Current situation and future expectations | Semantic Scholar

TECARTUS® Efficacy - Response Data for R/R MCL
TECARTUS® Efficacy - Response Data for R/R MCL

iLLUMINATE - Overall Response Rate | IMBRUVICA® (ibrutinib) HCP
iLLUMINATE - Overall Response Rate | IMBRUVICA® (ibrutinib) HCP

ORR (Objective Response Rate) and related statistics – Part 1
ORR (Objective Response Rate) and related statistics – Part 1

High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis | Blood Cancer Journal
High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis | Blood Cancer Journal

Confirmed ORR and Median DOR | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Confirmed ORR and Median DOR | ENHERTU® (fam-trastuzumab deruxtecan-nxki)

Overall response rate | Download Table
Overall response rate | Download Table

Durable Response Rate
Durable Response Rate

ODOMZO® (sonidegib) | Efficacy Data
ODOMZO® (sonidegib) | Efficacy Data

PDF] Objective response rate assessment in oncology: Current situation and future expectations | Semantic Scholar
PDF] Objective response rate assessment in oncology: Current situation and future expectations | Semantic Scholar

Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know

Durable Response Rate
Durable Response Rate

ORR (Objective Response Rate) and related statistics – Part 1
ORR (Objective Response Rate) and related statistics – Part 1

Best Overall Response Rate (full analysis population) | Download Table
Best Overall Response Rate (full analysis population) | Download Table

Overall Response Rates - WM | IMBRUVICA® (ibrutinib) HCP
Overall Response Rates - WM | IMBRUVICA® (ibrutinib) HCP

Confirmed ORR and Median DOR | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Confirmed ORR and Median DOR | ENHERTU® (fam-trastuzumab deruxtecan-nxki)

Efficacy endpoints in Oncology
Efficacy endpoints in Oncology